| Title | Recent advances in the development of β-lactamase inhibitors |
|---|---|
| Author | Shivakumar S. Jalde and Hyun Kyung Choi* |
| Address | Department of Medicinal Chemistry, Jungwon University, Goesan 28420, Republic of Korea |
| Bibliography | Journal of Microbiology, 58(8),633–647, 2020, |
| DOI | 10.1007/s12275-020-0285-z |
| Key Words | β-lactamase inhibitors, anti microbial resistance (AMR), serine-β-lactamase, metallo-β-lactamases (MBL), diazabicyclooctanes (DBO), boronic acids |
| Abstract | β-Lactam antibiotics are the most commonly prescribed antibiotics worldwide; however, antimicrobial resistance (AMR) is a global challenge. The β-lactam resistance in Gram-negative bacteria is due to the production of β-lactamases, including extended-spectrum β-lactamases, metallo-β-lactamases, and carbapenem-hydrolyzing class D β-lactamases. To restore the efficacy of BLAs, the most successful strategy is to use them in combination with β-lactamase inhibitors (BLI). Here we review the medically relevant β-lactamase families and penicillins, diazabicyclooctanes, boronic acids, and novel chemical scaffold-based BLIs, in particular approved and under clinical development. |